IRMD
IRADIMED CORPORATION
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
-14/100
Last price
84.82
▼ 1.65 (1.91%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
86.47
Prev close
86.47
Day high
87.08
Day low
84.41
Volume
118.61K
Market cap
$1.08B
P/E (TTM)
48.19
52W range
71.34 – 107.90
Day trading desk
Gap from prior close
-0.00%
Prior close 86.47
VWAP
85.13
-0.37% from price
Relative volume
0.80×
Normal
Session range
4.25%
84.41 – 88.00
Position in range
11%
Near session low
ATR (14D)
2.14
2.53% of price
Prior day high
86.61
PDH
Prior day low
85.00
PDL
Bid / ask spread
—
Quote not published
Session volume
101.71K
Avg 127.38K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.90%
-3.8%
1M
+1.64%
+0.5%
3M
-11.93%
-16.4%
6M
-9.27%
-27.5%
YTD
-12.81%
-27.1%
1Y
+19.06%
+2.6%
3Y
+91.17%
+8.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on IRMD open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-53.62K
Net selling
Buy transactions
1
5.80K shares
Sell transactions
10
59.42K shares
Net transactions
+11
Buys less sells
Sell : buy shares
10.3 : 1
Heavily one-sided
Insider-held shares
4.50M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 3, 26 | ALLEN MONTY K Director |
SELL | 1.42K | $122.62K | Direct |
| Jun 18, 26 | GLENN JOHN F Chief Financial Officer |
— | 5.80K | — | Direct |
| Jun 4, 26 | SCHAREN-GUIVEL HILDA FREDERIQUE Director |
SELL | 3.00K | $285.00K | Direct |
| Jun 1, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 2.50K | $226.51K | Indirect |
| May 27, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $691.04K | Indirect |
| May 19, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $657.26K | Indirect |
| May 12, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $631.34K | Indirect |
| May 5, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $642.86K | Indirect |
| Apr 28, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $657.71K | Indirect |
| Apr 21, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $694.12K | Indirect |
| Apr 14, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $697.19K | Indirect |
| Apr 7, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $717.21K | Indirect |
| Mar 30, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $712.61K | Indirect |
| Mar 24, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $752.61K | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALLEN MONTY K |
Director | 19.58K | Sale |
CHIPRIN JEFF |
Officer | 687 | Conversion of Exercise of derivative security |
GLENN JOHN F |
Chief Financial Officer | 11.94K | Conversion of Exercise of derivative security |
HAWKINS JAMES B |
Director | 29.65K | Conversion of Exercise of derivative security |
SCHAREN-GUIVEL HILDA FREDERIQUE |
Director | 5.60K | Sale |
SUSI ROGER E |
Chief Executive Officer | — | Sale |
VUOTO ANTHONY F |
Director | 17.18K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$1.08B
Enterprise value$1.03B
Revenue (TTM)$86.34M
Gross profit$65.50M
EBITDA$29.18M
Net income$23.05M
EPS (TTM)$1.76
Free cash flow$16.20M
Total cash$59.08M
Total debt$0
Book value / share$7.96
Shares outstanding12.79M
Float8.33M
Short % of float8.44%
Dividend yield0.94%
Beta (5Y)0.91
Valuation & profitability ratios
Trailing P/E48.19
Forward P/E34.57
PEG ratio—
Price / sales—
Price / book10.66
EV / revenue11.88
EV / EBITDA35.14
Gross margin75.86%
Operating margin31.23%
Profit margin26.70%
Return on equity23.52%
Return on assets15.56%
Debt / equity—
Current ratio9.46
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $83.81M | $73.24M | $65.56M | $53.30M | +14.4% |
| Operating revenue | $83.81M | $73.24M | $65.56M | $53.30M | +14.4% |
| Cost of revenue | $19.49M | $16.89M | $15.40M | $12.02M | +15.4% |
| Gross profit | $64.32M | $56.35M | $50.16M | $41.28M | +14.2% |
| Research & development | $2.98M | $2.83M | $2.86M | $2.28M | +5.0% |
| Selling, general & admin | $35.20M | $31.55M | $27.26M | $23.38M | +11.6% |
| Total operating expense | $38.18M | $34.38M | $30.12M | $25.65M | +11.0% |
| Operating income | $26.15M | $21.96M | $20.04M | $15.63M | +19.0% |
| Net interest income | $2.01M | $2.19M | $1.86M | $581.85K | -8.4% |
| Pre-tax income | $28.36M | $24.27M | $21.74M | $16.18M | +16.8% |
| Tax provision | $5.88M | $5.04M | $4.55M | $3.35M | +16.7% |
| Net income | $22.48M | $19.23M | $17.19M | $12.83M | +16.9% |
| Net income to common | $22.48M | $19.23M | $17.19M | $12.83M | +16.9% |
| Basic EPS | 1.77 | 1.52 | 1.36 | 1.02 | +16.4% |
| Diluted EPS | 1.75 | 1.50 | 1.35 | 1.02 | +16.7% |
| EBIT | $26.15M | $21.96M | $20.04M | $15.63M | +19.0% |
| EBITDA | $27.31M | $22.78M | $20.80M | $16.30M | +19.9% |
| Basic shares | 12.72M | 12.67M | 12.60M | 12.56M | +0.4% |
| Diluted shares | 12.85M | 12.78M | 12.72M | 12.64M | +0.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $51.16M | $52.23M | $49.76M | $57.96M | -2.1% |
| Cash & short-term investments | $51.16M | $52.23M | $49.76M | $57.96M | -2.1% |
| Accounts receivable | $13.67M | $10.56M | $12.22M | $13.27M | +29.5% |
| Inventory | $11.62M | $10.40M | $12.82M | $5.37M | +11.7% |
| Total current assets | $81.20M | $75.24M | $76.00M | $77.49M | +7.9% |
| Property, plant & equipment | $23.86M | $16.81M | $11.33M | $4.61M | +41.9% |
| Goodwill & intangibles | $3.38M | $3.10M | $2.52M | $2.07M | +9.2% |
| Total assets | $108.78M | $98.33M | $92.16M | $85.51M | +10.6% |
| Total current liabilities | $10.18M | $8.51M | $16.33M | $8.55M | +19.6% |
| Total debt | $0 | $2.00K | $2.04M | $2.21M | -100.0% |
| Total liabilities | $14.16M | $11.51M | $20.74M | $11.84M | +23.0% |
| Retained earnings | $64.23M | $56.79M | $43.26M | $47.26M | +13.1% |
| Shareholder equity | $94.62M | $86.82M | $71.42M | $73.67M | +9.0% |
| Working capital | $71.02M | $66.73M | $59.67M | $68.94M | +6.4% |
| Net tangible assets | $91.23M | $83.72M | $68.90M | $71.60M | +9.0% |
| Shares issued | 12.78M | 12.71M | 12.66M | 12.59M | +0.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $22.48M | $19.23M | $17.19M | $12.83M | +16.9% |
| Depreciation & amortisation | $1.17M | $818.00K | $765.18K | $670.67K | +42.5% |
| Stock-based compensation | $2.92M | $2.52M | $2.19M | $1.39M | +15.6% |
| Change in working capital | -$4.34M | $3.75M | -$5.91M | -$5.06M | -215.9% |
| Operating cash flow | $24.95M | $25.62M | $13.47M | $10.04M | -2.6% |
| Capital expenditure | -$8.42M | -$8.82M | -$8.01M | -$1.87M | +4.5% |
| Investing cash flow | -$8.42M | -$8.82M | -$8.01M | -$1.37M | +4.5% |
| Dividends paid | -$15.04M | -$13.68M | -$13.22M | -$12.56M | -10.0% |
| Financing cash flow | -$17.60M | -$14.34M | -$13.66M | -$12.71M | -22.8% |
| Free cash flow | $16.53M | $16.81M | $5.46M | $8.17M | -1.7% |
| End cash position | $51.16M | $52.23M | $49.76M | $57.96M | -2.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $20.47M | $21.98M | $22.69M | $21.20M | $20.41M | -6.9% |
| Operating revenue | $20.47M | $21.98M | $22.69M | $21.20M | $20.41M | -6.9% |
| Cost of revenue | $5.31M | $5.17M | $5.66M | $4.71M | $4.45M | +2.7% |
| Gross profit | $15.16M | $16.81M | $17.03M | $16.49M | $15.96M | -9.8% |
| Research & development | $657.00K | $956.00K | $799.03K | $674.36K | $877.00K | -31.3% |
| Selling, general & admin | $8.11M | $8.62M | $9.14M | $8.99M | $8.29M | -5.9% |
| Total operating expense | $8.77M | $9.58M | $9.94M | $9.66M | $9.17M | -8.4% |
| Operating income | $6.39M | $7.24M | $7.09M | $6.83M | $6.79M | -11.7% |
| Pre-tax income | $6.89M | $7.77M | $7.79M | $7.30M | $7.33M | -11.3% |
| Tax provision | $1.67M | $1.95M | $1.35M | $1.72M | $1.55M | -14.4% |
| Net income | $5.22M | $5.82M | $6.44M | $5.58M | $5.77M | -10.3% |
| Net income to common | $5.22M | $5.82M | $6.44M | $5.58M | $5.77M | -10.3% |
| Basic EPS | 0.41 | 0.46 | 0.51 | 0.44 | 0.45 | -10.9% |
| Diluted EPS | 0.41 | 0.45 | 0.50 | 0.43 | 0.45 | -8.9% |
| EBIT | $6.39M | $7.24M | $7.09M | $6.83M | $6.79M | -11.7% |
| EBITDA | $6.80M | $7.69M | $7.47M | $7.22M | $7.00M | -11.6% |
| Basic shares | 12.78M | 12.78M | 12.74M | 12.72M | 12.72M | +0.0% |
| Diluted shares | 12.87M | 12.87M | 12.88M | 12.86M | 12.84M | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $59.08M | $56.37M | $51.16M | $56.53M | $53.00M | — | +4.8% |
| Cash & short-term investments | $59.08M | $56.37M | $51.16M | $56.53M | $53.00M | — | +4.8% |
| Accounts receivable | $13.19M | $13.41M | $13.67M | $13.86M | $10.92M | — | -1.7% |
| Inventory | $12.26M | $11.88M | $11.62M | $11.73M | $11.20M | — | +3.1% |
| Total current assets | $86.72M | $86.42M | $81.20M | $84.92M | $77.37M | — | +0.3% |
| Property, plant & equipment | $24.21M | $24.23M | $23.86M | $23.79M | $22.94M | — | -0.1% |
| Goodwill & intangibles | $3.44M | $3.29M | $3.38M | $3.37M | $3.37M | — | +4.6% |
| Total assets | $114.97M | $114.39M | $108.78M | $114.72M | $106.45M | — | +0.5% |
| Total current liabilities | $9.16M | $12.12M | $10.18M | $12.80M | $8.81M | — | -24.4% |
| Total debt | — | — | $0 | $0 | $0 | $59.22K | — |
| Total liabilities | $13.23M | $15.88M | $14.16M | $16.37M | $12.15M | — | -16.7% |
| Retained earnings | $70.15M | $67.49M | $64.23M | $66.34M | $62.93M | — | +3.9% |
| Shareholder equity | $101.75M | $98.51M | $94.62M | $98.35M | $94.30M | — | +3.3% |
| Working capital | $77.56M | $74.30M | $71.02M | $72.12M | $68.56M | — | +4.4% |
| Net tangible assets | $98.31M | $95.23M | $91.23M | $94.98M | $90.93M | — | +3.2% |
| Shares issued | 12.79M | 12.78M | 12.78M | 12.72M | 12.72M | — | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $5.22M | $5.82M | $6.44M | $5.58M | $5.77M | -10.3% |
| Depreciation & amortisation | $410.00K | $455.00K | $380.68K | $383.32K | $208.00K | -9.9% |
| Stock-based compensation | $807.00K | $684.00K | $696.24K | $665.76K | $731.00K | +18.0% |
| Change in working capital | -$344.00K | $1.42M | -$3.95M | $222.62K | $872.00K | -124.3% |
| Operating cash flow | $5.94M | $8.29M | $5.92M | $6.99M | $7.75M | -28.3% |
| Capital expenditure | -$443.00K | -$469.00K | -$416.41K | -$1.26M | -$2.82M | +5.5% |
| Investing cash flow | -$443.00K | -$469.00K | -$416.41K | -$1.26M | -$2.82M | +5.5% |
| Dividends paid | -$2.56M | -$2.56M | -$8.55M | -$2.16M | -$2.16M | -0.0% |
| Financing cash flow | -$2.79M | -$2.61M | -$10.87M | -$2.19M | -$2.26M | -7.1% |
| Free cash flow | $5.50M | $7.82M | $5.51M | $5.72M | $4.92M | -29.7% |
| End cash position | $59.08M | $56.37M | $51.16M | $56.53M | $53.00M | +4.8% |
Options analytics
Put / call volume
0.48
Call-heavy session
Put / call open interest
1.75
Positioning, not flow
Max pain
70.00
-17.5% from spot
ATM implied vol
0.4%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
33
Contracts, this expiry
Put volume
16
Contracts, this expiry
Heaviest call OI
110.00
5 contracts
Heaviest put OI
65.00
8 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.44 | 0.46 | +4.6% |
| Mar 2026 | 0.45 | 0.49 | +10.1% |
| Dec 2025 | 0.48 | 0.54 | +12.5% |
| Sep 2025 | 0.46 | 0.47 | +3.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.55 | 3 | $23.43M | +10.5% |
| Next quarter | 0.63 | 3 | $26.23M | +15.6% |
| Current year | 2.11 | 3 | $92.07M | +9.9% |
| Next year | 2.45 | 3 | $104.10M | +13.1% |
Analyst targets & ownership
Mean target$118.00
High target$120.00
Low target$116.00
Implied upside39.12%
Analyst count2
ConsensusBUY
Strong buy / Buy0 / 2
Hold1
Sell / Strong sell0 / 0
Held by insiders35.18%
Held by institutions62.67%
Institutions holding308
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
85.86
-1.22% from price
SMA 20
84.38
+0.52% from price
SMA 50
87.02
-2.53% from price
SMA 100
90.43
-6.20% from price
SMA 200
93.57
-9.35% from price
EMA 12
85.39
-0.66% from price
EMA 26
85.60
-0.91% from price
EMA 50
87.02
-2.52% from price
RSI (14)
46.2
Neutral
MACD (12,26,9)
-0.21
Hist 0.33
ATR (14)
2.14
2.53% of price
Realised vol 30D
21.7%
Annualised
Bollinger upper
87.96
20, 2σ
Bollinger lower
80.80
20, 2σ
50 / 200 cross
Death
87.02 vs 93.57
Trend bias
Below 200
-9.35%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.58
Less volatile than market
Correlation to SPY
0.24
Largely independent
Realised vol 30D
21.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-22.1%
Peak to trough
Max drawdown 5Y
-49.4%
Peak to trough
ATR 14
2.14
2.53% of price
Beta (reported)
0.91
5Y monthly, from filing
Short interest
Shares short
700.00K
Prior 727.75K
Change vs prior
-3.8%
Shorts covering
% of float
8.44%
Normal
% of shares out
5.47%
Against total outstanding
Days to cover
6.8
Crowded exit
Float
8.33M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 22, 26 | Needham | INITIATED | — | Hold |
| Apr 2, 26 | Freedom Broker | INITIATED | — | Buy |
| Feb 14, 25 | Roth MKM | MAINTAINED | Buy | Buy |
| Aug 2, 24 | Roth MKM | MAINTAINED | Buy | Buy |
| Aug 2, 21 | Roth Capital | MAINTAINED | — | Buy |
| Jul 31, 17 | Roth Capital | UPGRADE | Neutral | Buy |
| Oct 5, 16 | Roth Capital | DOWNGRADE | Buy | Neutral |
| Apr 4, 16 | Roth Capital | MAINTAINED | — | Buy |
| Jun 16, 15 | Roth Capital | MAINTAINED | — | Buy |
| Aug 11, 14 | Roth Capital | INITIATED | — | — |
Dividends & splits
Forward rate$0.80 / yr
Forward yield0.94%
5-year avg yield—
Payout ratio41.34%
Ex-dividend dateAug 14, 2026
Next pay dateAug 28, 2026
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K/A · 2026-08-18
Periodic Financial Reports
10-Q · 2026-07-31
Corporate Changes & Voting Matters
8-K · 2026-06-24
Periodic Financial Reports
10-Q · 2026-05-01
Proxy Statements
DEF 14A · 2026-04-30
Periodic Financial Reports
10-K · 2026-03-06
Corporate Changes & Voting Matters
8-K · 2026-02-10
Corporate Changes & Voting Matters
8-K · 2025-12-08
Headlines
IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference
GlobeNewswire · 14d ago
Market Strategist Julie Biel: The AI Craze Is Making These Quality Stocks More Affordable
Barrons.com · 16d ago
IRadimed (IRMD) Q2 2026 Earnings Call Transcript
Motley Fool · 60d ago
How IRADIMED's Modest Q2 Beat and Reaffirmed 2026 Guidance Will Impact IRMD Investors
Simply Wall St. · 60d ago
Replacement Cycle Anchors IRadimed Corp.’s (IRMD) Long Term Growth
Insider Monkey · 61d ago
iRadimed Corp (IRMD) (Q2 2026) Earnings Call Highlights: Strong Demand for New 3,870 Pump ...
GuruFocus.com · 64d ago
IRadimed Corporation Q2 2026 Earnings Call Summary
Moby · 67d ago
iRadimed Q2 Earnings Call Highlights
MarketBeat · 67d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.